Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.

Kesselheim AS, Mello MM, Studdert DM.

PLoS Med. 2011 Apr;8(4):e1000431. doi: 10.1371/journal.pmed.1000431. Epub 2011 Apr 5.

2.
3.

Investigating pharmaceutical marketing in Canada using American prosecutions.

Shoucri R, Persaud N.

Int J Risk Saf Med. 2014;26(3):147-53. doi: 10.3233/JRS-140619.

PMID:
25214160
4.

Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?

Joseph JN, Deaton D, Ehsan H, Bonanno MA.

J Health Life Sci Law. 2009 Jan;2(2):73-108.

PMID:
19288889
5.

Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.

Bagley CE, Mitts J, Tinsley RJ.

Cornell J Law Public Policy. 2013 Winter;23(2):337-93.

PMID:
25330567
6.

Media coverage of off-label promotion: a content analysis of US newspapers.

Joshi AD, Patel DA, Holdford DA.

Res Social Adm Pharm. 2011 Sep;7(3):257-71. doi: 10.1016/j.sapharm.2010.06.003. Epub 2010 Nov 25.

PMID:
21272550
7.

Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.

Kesselheim AS, Wang B, Studdert DM, Avorn J.

PLoS Med. 2012;9(8):e1001280. doi: 10.1371/journal.pmed.1001280. Epub 2012 Aug 7.

9.

Recent case developments in health law. False Claims Act: the right treatment for off-label marketing?

Wang S.

J Law Med Ethics. 2010 Fall;38(3):708-13. doi: 10.1111/j.1748-720X.2010.00524.x. No abstract available.

PMID:
20880253
11.

Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.

O'Reilly J, Dalal A.

Ann Health Law. 2003 Summer;12(2):295-324, table of contents.

PMID:
12856461
12.

False Claims Act prosecution did not deter off-label drug use in the case of neurontin.

Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J.

Health Aff (Millwood). 2011 Dec;30(12):2318-27. doi: 10.1377/hlthaff.2011.0370.

13.

Regulating off-label promotion of medications: has the pendulum swung too far?

Hoffman MB, Yentzer BA, Feldman SR.

Skin Therapy Lett. 2015 May-Jun;20(3):1-4.

14.

Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.

Kalb PE, Greenberg PE.

Pharmacoeconomics. 2009;27(8):623-5. No abstract available.

PMID:
19835018
15.

Clinical trial transparency--antidote to weaker off-label-promotion rules?

Outterson K.

N Engl J Med. 2014 Jul 3;371(1):1-3. doi: 10.1056/NEJMp1402969. No abstract available.

16.

Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.

Larkin I, Ang D, Avorn J, Kesselheim AS.

Health Aff (Millwood). 2014 Jun;33(6):1014-23. doi: 10.1377/hlthaff.2013.0939.

17.

Pfizer settles largest ever fraud suit for off-label promotion.

Ratner M.

Nat Biotechnol. 2009 Nov;27(11):961-2. doi: 10.1038/nbt1109-961. No abstract available.

PMID:
19898429
18.

Off-label drug use and promotion: balancing public health goals and commercial speech.

Kesselheim AS.

Am J Law Med. 2011;37(2-3):225-57. No abstract available.

PMID:
21847880
19.

No relaxing for relators: Stringent pleading requirements result in frequent dismissal of FCA claims for off-label marketing.

Clark JC, Sullivan JA.

Health Care Law Mon. 2009 Mar;2009(3):2-9. No abstract available.

PMID:
19388590
20.

["Off label" use of some medicinal products. Part I].

Sirakov M.

Akush Ginekol (Sofiia). 2012;51(2):29-32. Review. Bulgarian.

PMID:
23234011

Supplemental Content

Support Center